
The Lead Podcast presented by Heart Rhythm Society
by The Lead Podcast presented by Heart Rhythm Society
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 19 chart positions in 19 markets.
By chart position
- 🇬🇧GB · Courses#6630K to 100K
- 🇦🇺AU · Courses#1875K to 30K
- 🇯🇵JP · Courses#6410K to 30K
- 🇰🇷KR · Courses#1281K to 10K
- 🇮🇹IT · Courses#1451K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
23K to 89K🎙 Daily cadence·152 episodes·Last published 1w ago - Monthly Reach
Unique listeners across all episodes (30 days)
77K to 297K🇬🇧34%🇦🇺10%🇯🇵10%+16 more - Active Followers
Loyal subscribers who consistently listen
31K to 119K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 20 epsHosts
Recent guests
Recent episodes
The Lead Episode 156: A Discussion of The Association Between Atrial Fibrillation Burden and Quality of Life: A Substudy of the SHAM-PVI Trial
Jun 18, 2026
Unknown duration
The Lead Episode 155: A Discussion of A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD)
Jun 11, 2026
21m 35s
The Lead Episode 154: A Discussion of Safety and Effectiveness of a Dual-Energy Focal Ablation Catheter to Treat Paroxysmal Atrial Fibrillation: 6- Month Results of the FlexPulse IDE Study
Jun 4, 2026
25m 37s
The Lead Episode 153: A Discussion of Exercise Capacity and Quality-of-Life Improvements after Catheter Ablation in Patients with Clinically Asymptomatic Persistent Atrial Fibrillation
May 28, 2026
18m 08s
The Lead Episode 152: A Discussion of Outcomes of Left Atrial Appendage Closure versus Oral Anticoagulation in Patients with Atrial Fibrillation and Prior Ablation: A Sub-Analysis of the CHAMPION-AF Clinical Trial (New England Journal of Medicine)
May 21, 2026
22m 01s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/18/26 | ![]() The Lead Episode 156: A Discussion of The Association Between Atrial Fibrillation Burden and Quality of Life: A Substudy of the SHAM-PVI Trial | In this episode of The Lead, host Christopher Kowalewski, MD, is joined by John M. Mandrola, MD, and Nassir F. Marrouche, MD, FHRS, to discuss the journal article, The Association Between Atrial Fibrillation Burden and Quality of Life: A Substudy of the SHAM-PVI Trial. Together, they explore the relationship between atrial fibrillation burden and quality of life, reviewing findings from this substudy of the SHAM-PVI Trial and discussing their relevance to patient-centered outcomes. Learning Objectives Review the key findings from the SHAM-PVI Trial substudy examining the association between atrial fibrillation burden and quality of life. Discuss the relationship between atrial fibrillation burden and patient-reported quality-of-life outcomes. Explore the implications of assessing both arrhythmia burden and quality of life when evaluating treatment outcomes in atrial fibrillation. Host: Christopher Kowalewski, MD Guests: John M. Mandrola, MD and Nassir F. Marrouche, MD, FHRS Disclosures: Christopher Kowalewski, MD No relevant disclosures John M. Mandrola, MD No relevant disclosures Nassir F. Marrouche, MD, FHRS • Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Biosense Webster, Inc., Boston Scientific, AtriCure, Inc., Abbott, Sanofi • Research: Abbott, Biosense Webster, Inc., Medtronic, Siemens, General Electric, Boston Scientific, Sanofi, Samsung | — | ||||||
| 6/11/26 | ![]() The Lead Episode 155: A Discussion of A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD)✨ | pulsed field ablationanti-arrhythmic drug therapy+3 | Edward P. Gerstenfeld, MD, MS, FHRSPaul C. Zei, MD, PhD, FHRS | Medtronic, Inc.Biotronik+5 | — | pulsed field ablationanti-arrhythmic drugs+3 | — | 21m 35s | |
| 6/4/26 | ![]() The Lead Episode 154: A Discussion of Safety and Effectiveness of a Dual-Energy Focal Ablation Catheter to Treat Paroxysmal Atrial Fibrillation: 6- Month Results of the FlexPulse IDE Study✨ | dual-energy focal ablationparoxysmal atrial fibrillation+3 | Babak Nazer, MDRajesh Kabra, MD, FHRS | Medtronic, Inc.Edwards Lifesciences+7 | — | dual-energy focal ablation catheterparoxysmal atrial fibrillation+3 | — | 25m 37s | |
| 5/28/26 | ![]() The Lead Episode 153: A Discussion of Exercise Capacity and Quality-of-Life Improvements after Catheter Ablation in Patients with Clinically Asymptomatic Persistent Atrial Fibrillation✨ | exercise capacityquality of life+3 | Jenelle Dziano, PhD candidate, Clinical Exercise PhysiologistAdrian D. Elliott, PhD+2 | Exercise Capacity and Quality-of-Life Improvements after Catheter Ablation in Patients with Clinically Asymptomatic Persistent Atrial Fibrillation | — | catheter ablationexercise capacity+3 | — | 18m 08s | |
| 5/21/26 | ![]() The Lead Episode 152: A Discussion of Outcomes of Left Atrial Appendage Closure versus Oral Anticoagulation in Patients with Atrial Fibrillation and Prior Ablation: A Sub-Analysis of the CHAMPION-AF Clinical Trial (New England Journal of Medicine)✨ | left atrial appendage closureoral anticoagulation+4 | Jason T. Jacobson, MD, FHRSAmmar M. Killu, MBBS+1 | Heart Rhythm SocietyNew England Journal of Medicine+1 | — | left atrial appendage closureoral anticoagulation+7 | — | 22m 01s | |
| 5/21/26 | ![]() The Lead Episode 151: Heart Rhythm 2026 Late-Breaker Coverage: A Discussion of Outcomes of Left Atrial Appendage Closure versus Oral Anticoagulation in Patients with Atrial Fibrillation and Prior Ablation: A Sub-Analysis of the CHAMPION-AF Clinical Trial✨ | left atrial appendage closureoral anticoagulation+4 | Scott C. Brancato, MD, FHRS | WATCHMAN FLX deviceHeart Rhythm Society+1 | — | left atrial appendage closureoral anticoagulation+6 | — | 33m 09s | |
| 5/14/26 | ![]() The Lead Episode 148: HRS 2026 Late-Breaker Coverage, A Discussion of Ventricular Intramyocardial Navigation and Tachycardia Ablation Guided by Electrograms (VINTAGE): First-in-Human Experience with a Novel Therapy for Refractory Ventricular Arrhythmias✨ | ventricular arrhythmiascatheter-based navigation+4 | John L. Sapp, Jr., MD, FHRSKyoko Soejima, MD | Ventricular Intramyocardial Navigation and Tachycardia Ablation Guided by Electrograms (VINTAGE)Heart Rhythm Society | — | ventricular arrhythmiasablation+5 | — | 16m 27s | |
| 5/14/26 | ![]() The Lead Episode 150: Heart Rhythm 2026 Late-Breaker Coverage: A Discussion of Total Fatal Adverse Events Following Atrial Fibrillation Ablation Reported in an FDA Mandatory Reporting System: A Matter of Concern? The TiFFANY Study✨ | Atrial Fibrillation AblationFatal Adverse Events+3 | Christopher F. Liu, MD, FHRSJames Freeman, MD, MPH, Msci | Heart Rhythm SocietyFDA+2 | — | Atrial FibrillationAblation+5 | — | 18m 18s | |
| 5/14/26 | ![]() The Lead Episode 149: Heart Rhythm 2026 Late-Breaker Coverage: A Discussion of Safety and Performance of a Novel ICD Lead for Left Bundle Branch Area Pacing: Results from the ASCEND CSP Trial✨ | ICD technologyleft bundle branch area pacing+3 | Paul Chun Yih Lim, MBBS, FHRSAbhishek Deshmukh, MD | ICD leadHeart Rhythm Society | — | ICD leadleft bundle branch area pacing+5 | — | 15m 23s | |
| 5/7/26 | ![]() The Lead Episode 146: Late Breaker Coverage: A Discussion of LEAP2: A First-In-Human Study of a Chronically-Implanted Novel Leadless Pacemaker for Conduction System Pacing✨ | leadless pacemakerconduction system pacing+4 | Mihail G. Chelu, MD, PhD, FHRSDerek Chew, MD, MS, FHRS | leadless pacemakerHeart Rhythm Society | — | LEAP2 trialfirst-in-human study+4 | — | 22m 46s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 5/7/26 | ![]() The Lead Episode 145: Heart Rhythm 2026 Late Breaker Coverage: A Discussion of Cognitive Function and Anticoagulation Discontinuation in Patients Without Long-Term Recurrence After Catheter Ablation for Atrial Fibrillation✨ | cognitive functionanticoagulation discontinuation+4 | David H. Birnie, MDT. Jared Bunch, MD, FHRS | Heart Rhythm SocietyDigital Education Committee+1 | — | anticoagulationcognitive outcomes+5 | — | 14m 50s | |
| 5/7/26 | ![]() The Lead Episode 147: Heart Rhythm 2026 Late Breaker Coverage: A Discussion of Proton Beam Cardiac Radioablation for Refractory Ventricular Tachycardia: Results from a Frist-in-Human, Prospective, Non-Randomized Trial | Welcome to the third in this week's series of Lead episodes covering late breaking clinical trials from Heart Rhythm 2026 in Chicago. Join host Michael Lloyd, MD, FHRS, and his guests Christopher Kowalewski, MD and Karin Benali, MD, PhD for this discussion. This first-in-human, prospective study presented at Heart Rhythm 2026 evaluated noninvasive proton beam cardiac radioablation for patients with refractory ventricular tachycardia who had failed prior ablation and medical therapy. In a small, high-risk cohort, proton therapy was feasible and demonstrated substantial reductions in VT burden (approximately 80%) with no significant treatment-related toxicity observed during follow-up. These early findings highlight proton beam radioablation as a promising, highly targeted, noninvasive treatment option, though larger studies are needed to confirm long-term safety and durability. Learning Objectives: Describe the principles of cardiac radioablation and the advantages of proton beam therapy compared with photon-based approaches for treating ventricular tachycardia. Evaluate early feasibility, safety, and efficacy outcomes of proton beam therapy in patients with refractory ventricular tachycardia. Assess the potential role of noninvasive cardiac radioablation in the treatment algorithm for patients with drug- and ablation-refractory ventricular tachycardia. Podcast Contributors Michael S. Lloyd, MD, FHRS Christopher Kowalewski, MD Karin Benali, MD, PhD Host and Contributor Disclosure(s): M. Lloyd •Honoraria/Speaking/Teaching/Consulting: Medtronic •Membership on Advisory Committees: Boston Scientific K. Bemali Nothing to disclose. D. Chew Nothing to disclose. | — | ||||||
| 4/20/26 | ![]() A Message from The Lead Podcast Team for the Week of April 20, 2026✨ | Heart Rhythm 2026clinical trials+2 | — | The Lead Podcast | Chicago | Heart Rhythmclinical trials+3 | — | — | |
| 4/16/26 | ![]() The Lead Episode 144: A Discussion of Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial✨ | Atrial FibrillationSmartwatch Monitoring+3 | Marco PerezKristie Coleman | Apple WatchHeart Rhythm Society | — | Atrial FibrillationApple Watch+6 | — | 24m 52s | |
| 4/9/26 | ![]() The Lead Episode 143: A Discussion of The Empirical Evidence in the Successful Anatomical Ablation of Idiopathic LV Summit Ventricular Arrhythmias✨ | anatomical ablationidiopathic LV summit ventricular arrhythmias+4 | Dr. Chi Keong Ching, MBBS, FHRSDr. Haris M. Haqqani, MD, PhD, FHRS | Heart Rhythm Society | — | anatomical challengescatheter ablation+4 | — | 20m 31s | |
| 4/2/26 | ![]() The Lead Episode 142: A Discussion of Class 1c Antiarrhythmic Therapy Following PCI in New Onset Atrial Fibrillation: Safety and Clinical Outcomes from a Nationwide Cohort✨ | Class 1c antiarrhythmic therapynew-onset atrial fibrillation+4 | Sandeep Gautam, MD, MPH, FHRSDeepak Padmanabhan, MD, FHRS | Australian National UniversityKauvery Hospital+2 | — | antiarrhythmic therapyatrial fibrillation+5 | — | 24m 21s | |
| 3/23/26 | ![]() The Lead the Week of Marh 23✨ | electrophysiologypodcast hiatus+1 | — | The Lead Podcast presented by Heart Rhythm Society | — | electrophysiologypodcast+3 | — | — | |
| 3/19/26 | ![]() The Lead Episode 141: A Discussion of Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis✨ | GLP-1 receptor agonist therapyatrial fibrillation+3 | Sheldon Litwin, MDAbhishek Deshmuckh, MBBS | glucagon-like peptide-1 receptor agonist (GLP-1RA)Medical University of South Carolina+1 | — | GLP-1RAatrial fibrillation+5 | — | 20m 22s | |
| 3/12/26 | ![]() The Lead Episode 140: A Discussion of Atrial Cardiomyopathy: Markers and Outcomes✨ | Atrial CardiomyopathyAF risk prediction+4 | Joshua Silverstein MD, FHRSJonathan Ariyaratnam, BChir, MA, MB, CCDS, CEPS-A | Allegheny Health NetworkUniversity of Adelaide+1 | — | Atrial CardiomyopathyAF+6 | — | 20m 56s | |
| 3/5/26 | ![]() The Lead Episode 139: A Discussion of Improving Outcomes of Atrial Fibrillation Ablation by Integrated Personalized Lifestyle Interventions: A Randomized Control Trial✨ | Atrial FibrillationLifestyle Interventions+3 | Nino Isakadze, MD, MHSGeraldine A. Lee, PhD, FESC | Heart Rhythm Society | — | Atrial Fibrillationablation+5 | — | 30m 00s | |
| 2/26/26 | ![]() The Lead Episode 138: A Discussion of Safety, Efficacy, and Mid-Term Outcomes of Pulsed Field Ablation for Cavotricuspid Isthmus–Dependent Flutter: Real-World Data From a Major Health System Registry✨ | pulsed field ablationcavotricuspid isthmus-dependent flutter+4 | Senthil Thambidorai, MD, FHRSLee Karl Thien, MD, CCDS | — | — | pulsed field ablationCTI-dependent atrial flutter+4 | — | 28m 22s | |
| 2/19/26 | ![]() The Lead Episode 137: A Discussion of Impact of Hospital VT Ablation Volume on Post-Procedural Complications✨ | hospital VT ablation volumepost-procedural complications+4 | Jackson J. Liang, DOEdward P. Gerstenfeld, MD, MS, FHRS | — | — | ventricular tachycardiaablation volume+5 | — | 23m 02s | |
| 2/12/26 | ![]() The Lead Episode 136: A Discussion of Electrophysiological Characteristics of Lead Position Dependent Electrogram Uninterrupted Transition during Left Bundle Branch Pacing | Join Digital Education Committee Member and podcast host Jason T. Jacobson, MD, FHRS, along with this week's guest contributors, Gaurav A. Upadhyay, MD, FHRS and Pugazhendhi Vijayaraman, MD, FHRS for this exciting conversation! This Heart Rhythm Journal article explores the electrophysiologic signatures that occur during left bundle branch pacing (LBBP) as lead position changes, with a focus on identifying "uninterrupted transition" patterns in recorded electrograms. The findings help clarify how subtle lead movement within the interventricular septum can alter electrogram morphology and capture behavior, improving clinicians' ability to confirm true conduction system engagement during implantation. Read the article Learning Objectives Describe the electrophysiologic basis of lead position–dependent electrogram changes observed during left bundle branch pacing. Differentiate uninterrupted transition electrogram patterns from other pacing capture transitions (e.g., septal capture vs LBB capture). Apply electrogram transition findings to improve procedural decision-making for confirming optimal lead placement during LBBP implantation. Article AuthorsJiabo Shen, MD, Longfu Jiang, MD, Hao Wu, MD, Lu Zhang, MD, Hengdong Li, MD, Lifang Pan, MD Podcast ContributorsGaurav A. Upadhyay, MD, FHRS Pugazhendhi Vijayaraman, MD, FHRS Jason T. Jacobson, MD, FHRS Host and Contributor Disclosure(s): J. Jacobson Honoraria/Speaking/Teaching/Consulting: Zoll Medical Corporation, Vektor Medical Inc. Stocks, Privately Held: Atlas 5D Research: CardioFocus, Inc. Membership on Advisory Committees: Abbott Medical, Johnson and Johnson G. Upadhyay Honoraria/Speaking/Teaching/Consulting: Boston Scientific, Abbott, Medtronic, Biontronik, Zoll Medical Corporation P. Vijayaraman Honoraria/Speaking/Consulting: Medtronic, Boston Scientific, Biotronik, Abbott Medical, Abbott Research: Medtronic Fellowship Support: Medtronic Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose. | — | ||||||
| 2/5/26 | ![]() The Lead Episode 135: A Discussion of Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extraction | Welcome to this week's episode of The Lead. Join HRS Digital Education Committee member and podcast host Danesh Kella, MBBS, FHRS as he welcomes his guests Rahul N Doshi, MD, FHRS and Robert D Schaller, DO, FHRS. They are discussing Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extractions, which was published in the Journal of the American College of Cardiology in October 2025. This article describes the use of mechanical vacuum aspiration systems to debulk large intracardiac vegetations during cardiac implantable electronic device (CIED) extraction, aiming to reduce embolic risk and procedural complications. The authors highlight procedural techniques, patient selection, and safety considerations when combining aspiration with transvenous lead extraction. This approach represents an important adjunctive strategy for managing complex CIED infections with large vegetations. Learning Objectives Describe the role of mechanical vacuum aspiration in the management of large vegetations during CIED extraction procedures. Identify patient selection criteria and procedural considerations for safely combining vegetation debulking with transvenous lead extraction. Recognize potential risks, benefits, and complications associated with aspiration-assisted extraction in patients with CIED infection. Article for Discussion: https://www.jacc.org/doi/10.1016/j.jacc.2025.07.043 Article Authors Yury Malyshev, Marc A. Miller, Anelechi Anyanwu, George C. Shaw, Mouhannad Sadek, Seth Newman, Sakshum Chadha, Maryam Saleem, Nana Gegechkori, Abhishek Maan, Daniel Musikantow, Mohit Turagam, William Whang, Joshua Lampert, Jacob Koruth, Srinivas Dukkipati, Eric Neibart, and Vivek Y. Reddy Podcast Contributors Danesh Kella, MBBS, FHRS Rahul N Doshi, MD, FHRS Robert D Schaller, DO, FHRS Host and Contributor Disclosure(s): D. Kella Honoraria/Speaking/Teaching/Consulting: Zoll Medical Corporation, MBW Spectrum R. Doshi Honoraria/Speaking/Teaching/Consulting: Boston Scientific, Kestra, Inc., Abbott, Impulse Dynamics R. Schaller Honoraria/Speaking/Consulting: Medtronic, Boston Scientific, Philips, Cook Medical Research: Abbott Medical Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose. | — | ||||||
| 1/29/26 | ![]() The Lead Episode 134: A Discussion of Bachmann Bundle Pacing Target: Retrograde Mapping and Microstructural Correlation | Join Digital Education Committee Member and podcast host Deep Chandh Raja, MBBS, MD, PhD , and his guests Georgios Leventopoulos, MD, and Muthiah Subramanian, MD, CCDS, CEPS-A, for this week's Lead episode. This Heart Rhythm article investigates the Bachmann bundle as a target for pacing by using retrograde electrical mapping and correlating findings with underlying myocardial microstructure. The piece provides detailed insights into how Bachmann bundle activation pathways relate to tissue architecture, with implications for optimizing physiologic pacing strategies. These findings may help refine pacing techniques that aim to better mimic natural conduction and improve clinical responses. Learning Objectives Describe the anatomical and electrophysiologic characteristics of the Bachmann bundle and its role in atrial conduction. Explain how retrograde mapping and microstructural correlation can identify optimal pacing targets within the atrial conduction system. Evaluate the potential clinical implications of Bachmann bundle pacing for achieving more physiologic atrial activation. Article AuthorsDaniel L. Lustgarten, MD, PhD, FHRS, Nicole Habel, MD, PhD, Margaret Infeld, MD, MS, Daniel Correa de Sa, MD, Robert Lobel, MD, Peter Spector, MD, FHRS, Nathaniel Thompson, MD, Joseph Winget, MD, Neal Duong, BME, Bo Ye, MD, PhD, Paul A. Iaizzo, PhD, Markus Meyer, MD, PhD Podcast Contributors Deep Chandh Raja, MBBS, MD, PhD Georgios Leventopoulos, MD Muthiah Subramanian, MD, CCDS, CEPS-A Article Being Discussed Host and Contributor Disclosure(s): G. Leventopolous Nothing to disclose. D.C. Raja Nothing to disclose. M. Subramanian •Nothing to disclose. | — | ||||||
Showing 25 of 160
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
19 placements across 19 markets.
Chart Positions
19 placements across 19 markets.
